These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38850771)

  • 1. CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases.
    Barba L; Bellomo G; Oeckl P; Chiasserini D; Gaetani L; Torrigiani EG; Paoletti FP; Steinacker P; Abu-Rumeileh S; Parnetti L; Otto M
    J Neurol Sci; 2024 Jul; 462():123059. PubMed ID: 38850771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.
    Nielsen HM; Minthon L; Londos E; Blennow K; Miranda E; Perez J; Crowther DC; Lomas DA; Janciauskiene SM
    Neurology; 2007 Oct; 69(16):1569-79. PubMed ID: 17761554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.
    van Steenoven I; Noli B; Cocco C; Ferri GL; Oeckl P; Otto M; Koel-Simmelink MJA; Bridel C; van der Flier WM; Lemstra AW; Teunissen CE
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
    Geng C; Tan L; Chen C
    Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.
    van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE
    Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Howard E; Irwin DJ; Rascovsky K; Nevler N; Shellikeri S; Tropea TF; Spindler M; Deik A; Chen-Plotkin A; Siderowf A; Dahodwala N; Weintraub D; Shaw LM; Trojanowski JQ; Vaishnavi SN; Wolk DA; Mechanic-Hamilton D; Morley JF; Duda JE; Grossman M; Cousins KAQ
    Neurology; 2021 Apr; 96(14):e1855-e1864. PubMed ID: 33593865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
    Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
    J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cerebrospinal fluid pressure and cognition in patients with Alzheimer's disease and Lewy body dementia.
    Yang X; Gan J; Ji Y
    BMC Neurol; 2024 Jan; 24(1):35. PubMed ID: 38243235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF.
    Boiten WA; van Steenoven I; Xiao MF; Worley PF; Noli B; Cocco C; Ferri GL; Lemstra AW; Teunissen CE
    Cells; 2020 Dec; 10(1):. PubMed ID: 33383752
    [No Abstract]   [Full Text] [Related]  

  • 15. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias.
    Said HM; Kaya D; Yavuz I; Dost FS; Altun ZS; Isik AT
    Clin Interv Aging; 2022; 17():467-477. PubMed ID: 35431542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.
    Coughlin DG; Phillips JS; Roll E; Peterson C; Lobrovich R; Rascovsky K; Ungrady M; Wolk DA; Das S; Weintraub D; Lee EB; Trojanowski JQ; Shaw LM; Vaishnavi S; Siderowf A; Nasrallah IM; Irwin DJ; McMillan CT;
    Neurobiol Aging; 2020 Dec; 96():137-147. PubMed ID: 33002767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework.
    Llano DA; Devanarayan P; Devanarayan V;
    Neurobiol Aging; 2023 Jan; 121():15-27. PubMed ID: 36368195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.